Neurology and obstetric specialists have consolidated the evidence on managing multiple sclerosis across the reproductive years, updating recommendations that had stood since 2014. The work screened 774 papers and pulled together drug-by-drug pregnancy and lactation data on the disease-modifying therapies now in use, then set consensus guidance on top of it.
The substance for an obstetrician is threefold. Multiple sclerosis itself does not, in most cases, raise the risk of adverse pregnancy outcomes, though some studies report modestly raised rates of lower birthweight, preterm birth and operative delivery. Disease activity can usually be held down through the childbearing period by continuing many disease-modifying therapies, or by timing them around conception, rather than by stopping treatment and waiting. And the postpartum period is where the risk concentrates — medically and psychologically — so it needs planned follow-up rather than a six-week discharge.
The reflex this challenges is the blanket wash-out. Women are still told to come off treatment before trying to conceive, which for some agents trades a small fetal exposure question for a real chance of relapse in the year that matters most. The agent matters; the answer is drug-specific, and it needs the neurologist in the conversation before conception, not after the test is positive.
There is also a gynaecological tail the review names explicitly: therapy-associated infection risk and cervical dysplasia surveillance once childbearing is complete, then the menopausal transition. These women stay in gynaecological care long after the obstetric episode ends.
- Ask about disease-modifying therapy at the preconception visit and contact the neurologist before anything is stopped
- Document the specific agent — pregnancy and lactation data differ sharply between drugs and cannot be generalised by class
- Plan postpartum neurology review and a mood screen into the discharge letter rather than leaving it to the six-week visit
- Do not assume breastfeeding and treatment are incompatible; check the agent
- Keep cervical screening on schedule in women on long-term immunomodulation
Why it matters
The instinct to stop treatment for pregnancy may be the riskier option, and the postpartum months are where relapse and low mood cluster.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for obstetrics & gynaecology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free